Schizophrenia Research
Volume 45, Issue 3 , Pages 191-201 , 27 October 2000

Phasic and enduring negative symptoms in schizophrenia: biological markers and relationship to outcome

Received 28 August 1998 ,Accepted 2 August 1999.

References 

  1. Altamura AC, Guercetti G, Percudani M. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res. 1989;30:69–75
  2. American Psychiatric Association . American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Revised 3rd edition. Washington, DC: American Psychiatric Association; 1987;
  3. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry. 1982;39:784–788
  4. Andreasen NC, Flaum M, Swayze VW, Tyrrel G, Arndt S. Positive and negative symptoms in schizophrenia: A critical appraisal. Arch. Gen. Psychiatry. 1982;47:615–621
  5. Andreasen NC, Olsen SA, Dennert JW, et al.  Ventricular enlargement in schizophrenia: relationship to positive and negative symptoms. Am. J. Psychiatry. 1982;139:297–302
  6. Andreasen NC. The Scale for the Assessment of Negative Symptoms. Iowa City, IA: University of Iowa; 1983;
  7. Barnes TRE, Liddle PF. Evidence for the validity of negative symptoms. In:  Andreasen NC editors. Schizophrenia Positive and Negative Symptoms and Syndromes. Basel: Karger; 1990;
  8. Bleuler E. Dementia Praecox or the Group of Schizophrenias. New York: International Universities Press; 1950;J. Zinki, Trans.
  9. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr. Bull. 1982;8:470–484
  10. Carpenter WT, Heinrichs DW, Aplhs LD. Treatment of negative symptoms. Schizophr. Bull. 1985;11:440–452
  11. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am. J. Psychiatry. 1988;145:578–583
  12. Carpenter WT. The treatment of negative symptoms: Pharmacological and methodological issues. Br. J. Psychiatry. 1996;168(Suppl. 29):17–22
  13. Carpenter WT. New views on the course and treatment of schizophrenia. J. Psychiatr. Res. 1998;32:175–179
  14. Crow TJ. Molecular pathology of schizophrenia: more than one disease process. Br. Med. J. 1980;280:66–68
  15. Crow TJ. Positive and negative symptoms of schizophrenia and the role of dopamine. Br. J. Psychiatry. 1980;137:383–386
  16. Davies N, Russell A, Jones P, Murray RM. Which characteristics of schizophrenia predate psychosis?. J. Psychiatr Res. 1998;32:120–128
  17. Davis KL, Buchasbaum MS, Shihabuddin L, Spiegel-Cohen J, Netzger M, Frecksa E, et al. Ventricular enlargement in poor-outcome schizophrenia. Biol. Psychiatry. 1998;43:783–793
  18. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. Schizophrenia as a chronic brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. Neuroimag. 1997;74:129–140
  19. DeLisi LE. Regional brain volume change over the life-time course of schizophrenia. J. Psychiatr. Res. 1999;33:in press
  20. DeQuardo JR, Tandon R, Goldman RS, Meador-Woodruff JH, McGrath M, Brunberg JA, et al. Ventricular enlargement, neuropsychological status, and premorbid function in schizophrenia. Biol. Psychiatry. 1994;35:517–524
  21. DeQuardo JR, Goldman RS, Tandon R, McGrath M, Kim L. Comparison of indices of premorbid function in schizophrenia. Schizophr. Res. 1995;15:283–290
  22. Endicott J, Spitzer RL. A diagnostic interview: the Schedule for Affective Disorders and Schizophrenia (SADS). Arch. Gen. Psychiatry. 1978;35:837–853
  23. Flaum M, Andreasen NC. The reliability of distinguishing primary versus secondary negative symptoms. Compr. Psychiatry. 1995;36:421–427
  24. Ganguli R, Reynolds CF, Kupfer DJ. Electroencephalographic sleep in young, never-medicated schizophrenics. Arch. Gen. Psychiatry. 1987;44:36–44
  25. Greden JF, Tandon R. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC: American Psychiatric Press; 1991;
  26. Jibson MD, Tandon R. The new atypical antipsychotic medications. J. Psychiat. Res. 1998;32:215–228
  27. Kane JM, Honigfeld G, Singer J, Meltzer HY. Clozapine for the treatment-ressitant schizophrenic: A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  28. Kay SR, Fiszbein A, Lindenmeyer JP, et al.  Positive and negative syndromes in schizophrenia as a function of chronicity. Acta Psychiatr. Scand. 1986;74:507–518
  29. Kay SR, Singh MM. The positive–negative distinction in drug-free schizophrenic patients: stability, response to neuroleptics, and prognostic significance. Arch. Gen. Psychiatry. 1989;46:711–718
  30. Kay SR. Longitudinal course of negative symptoms in schizophrenia. In:  Greden JF,  Tandon R editor. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC: American Psychiatric Press; 1991;
  31. Keshavan MS, Reynolds CF, Kupfer DJ. Electroencephalographic sleep in schizophrenia: A critical review. Compr. Psychiatry. 1990;30:34–47
  32. Keshavan MS, Tandon R. Sleep abnormalities in schizophrenia: pathophysiological significance. Psychol. Med. 1993;23:831–835
  33. Keshavan MS, Pettegrew JW, Reynolds CF, Panchalingam KS, Montrose D, Miewald J, et al. Slow-wave sleep deficit in schizophrenia: pathophysiological significance. Psychiatr. Res. 1995;51:91–100
  34. Keshavan MS, Reynolds CF, Miewald JM, Montrose DM. A longitudinal study of EEG sleep in schizophrenia. Psychiatry Res. 1996;59:203–211
  35. Keshavan MS, Reynolds CF, Miewald JM, Montrose DM, Sweeney JA, Vasko RC, et al. Delta sleep deficits in schizophrenia. Arch. Gen. Psychiatry. 1998;55:443–448
  36. Keshavan MS, Haas GL, Kahn CE, Aguilar E, Dick EL, Schooler NR, et al. Superior temporal gyrus and the course of schizophrenia: progressive, static, or reversible?. J. Psychiatr. Res. 1998;32:145–152
  37. Keshavan MS. Development, disease and degeneration in schizophrenia: A unitary pathophysiological model. J. Psychiatr. Res. 1999;33:in press
  38. Kraepelin E. In:  Barclay RM,  Robertson GM editor. Dementia Praecox and Paraphrenia. Edinburgh: E&S Livingstone; 1919;
  39. Marneros A, Andreasen NC, Tsuang MT. Negative versus Positive Schizophrenia. Berlin: Springer; 1991;
  40. Meltzer HY, Casey DE, Garver DL, Marder SR, Masand PS, Miller D, et al. Assessing the effects of atypical antipsychotics on negative symptoms.. J. Clin. Psychiatry. 1998;59(Suppl. 12):28–34
  41. Miller, D.D., Tandon, R., in press. The biology of pathophysiology of negative symptoms. In: Keefe, R., McEvoy, J., Negative Symptoms of Schizophrenia. American Psychiatric Association Press, Washington, DC, in press.
  42. Moller J-J, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytic approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 1995;245:45–49
  43. Nasrallah HA, Tolbert HA. Neurobiology and neuroplasticity in schizophrenia. Arch. Gen. Psychiatry. 1997;54:913–914
  44. Overall JE, Gorham DR. Brief Psychiatric Rating Scale. Psychol. Rep. 1962;10:799–812
  45. Pogue-Geile MF, Zubin J. Negative symptomatology in schizophrenia: a conceptual and empirical review. Int. J. Ment. Health. 1988;16:3–45
  46. Ribeiro SCM, Tandon R, Ricoy R, Mazzara C, Craig KA, Greden JF. Clinical predictors of one-year outcome in schizophrenia. Psychopathology. 1993;25:331–334
  47. Russell AJ, Munro J, Jones PB, Hemsley D, Murray RM. Schizophrenia and the myth of intellectual decline. Am. J. Psychiatry. 1997;154:635–639
  48. Schooler NR. Deficit symptoms in schizophrenia: negative symptoms versus neuroleptic-induced deficits. Acta. Psychiatr. Scand. 1994;89(Suppl. 380):21–26
  49. Schooler NR. Negative symptoms in schizophrenia: Assessment of the effect of risperidone. J. Clin. Psychiatry. 1994;55(Suppl. 5):22–28
  50. Spitzer RL, Endicott J, Robins E. Research Diagnostic Criteria (RDC): Rationale and reliability. Arch. Gen. Psychiatry. 1978;35:773–782
  51. Strauss J, Carpenter WT, Bartko J. The diagnosis and understanding of schizophrenia III: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr. Bull. 1974;1:61–69
  52. Strauss JS, Carpenter WT. Prediction of outcome in schizophrenia III. Five-year outcome and its predictors. Arch. Gen. Psychiatry. 1977;34:159–163
  53. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. Arch. Gen. Psychiatry. 1989;46:745–753
  54. Tandon R, Goldman RS, Goodson J, Greden JF. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol. Psychiatry. 1990;227:1323–1326
  55. Tandon R, Greden JF. Conclusion: Is integration possible?. In:  Greden JF,  Tandon R editor. Negative Schizophrenic Symptoms: Pathophysiology and Clinical Implications. Washington, DC: American Psychiatric Press; 1991;p. 233–239
  56. Tandon R, Mazzara C, DeQuardo JR, Craig KA, Meador-Woodruff JH, Goldman RS, et al. Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement and outcome. Biol. Psychiatry. 1991;29:953–964
  57. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J. Muscarinic cholinergic hyperactivity in schizophrenia: Relationship to positive and negative symptoms. Schizophr. Res. 1991;4:23–30
  58. Tandon R, Shipley JE, Taylor SF, Greden JF, Eiser A, DeQuardo JR, et al. Electroencephalographic sleep abnormalities in schizophrenia. Arch. Gen. Psychiatry. 1992;49:185–194
  59. Tandon R, Ribeiro SCM, DeQuardo JR, Goldman RS, Goodson J, Greden JF. Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: A replication. Biol. Psychiatry. 1993;34:495–497
  60. Tandon R, Goldman RS, DeQuardo JR, Goldman M, Perez M, Jibson M. Positive and negative symptoms covary during closapine treatment in schizophrenia. J. Psychiatr. Res. 1993;27:341–347
  61. Tandon R, Jibson M, Taylor SF, DeQuardo JR. The pathophysiology of positive and negative symptoms in schizophrenia. In:  Shriqui C,  Nasrallah HA editor. Contemporary Issues in the Treatment of Schizophrenia. Washington, DC: American Psychiatric Press; 1995;p. 109–124
  62. Tandon R, Lewis C, Taylor SF, Shipley JE, DeQuardo JR, Jibson M, et al. Relationship between DST nonsuppression and shortened REM latency in schizophrenia. Biol. Psychiatry. 1996;40:660–663
  63. Tandon R. Cholinergic aspects of schizophrenia. Br. J. Psychiatry. 1999;173(Suppl. 37):7–11
  64. Tandon R. Moving beyond findings: Constructs and model-building in schizophrenia. J. Psychiatr. Res. 1999;33:in press
  65. Tandon R, DeQuardo J, Taylor SF. Neurobiology of schizophrenia. In:  Ananth J editors. Textbook of Psychopharmacology. New Delhi: Jaypee Brothers; 1999;p. 210–231
  66. Tandon R, Taylor SF, DeQuardo JR, Shipley JE, Eiser A, Jibson MD. The cholinergic system in schizophrenia reconsidered: Anticholinergic modulation of sleep and symptom profiles. Neuropsychopharmacology. 1999;in press
  67. Tandon R, Milner K, Jibson M. Antipsychotics from theory to practice: Integrating clinical and basic data. J. Clin. Psychiatry. 1999;60(Suppl. 8):21–28
  68. Taylor SF, Goldman RS, Tandon R, Shipley JE. Neuropsychological function and REM sleep in schizophrenic patients. Biol. Psychiatry. 1992;32:529–538
  69. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am. J. Psychiatry. 1997;154:466–474
  70. vanKammen DP, Hommer DW, Malas KL. Effect of pimozide on positive and negative symptoms in schizophrenic patients: Are negative symptoms state-dependent?. Neuropsychobiology. 1987;18:113–117
  71. Waddington JL, Buckley PF, Scully PJ, Lane A, O'Callaghan E, Larkin C. Course of psychopathology, cognition, and neurobiological abnormality in schizophrenia: Developmental origins and amelioration by antipsychotics. J. Psychiatr. Res. 1998;32:169–174
  72. Waddington JL, Lane A, Scully P, Meagher D, Quinn J, Larkin C, et al. Early cerebro-craniofacial dysmorphogenesis in schizophrenia: A lifetime trajectory model from neurodevelopmental basis to ‘neuroprogressive’ process. J. Psychiatr. Res. 1999;33:in press
  73. Zarcone VP, Benson KL, Berger PA. Abnormal rapid eye movement latencies in schizophrenia. Arch. Gen. Psychiatry. 1987;44:45–48
  74. Zarcone VP, Benson KL. Sleep and schizophrenia. In:  Kryger MH,  Roth T,  Dement WC editor. Principles and Practice of Sleep Medicine. New York: W.B. Sanders; 1994;p. 914–927

PII: S0920-9964(99)00163-2

Schizophrenia Research
Volume 45, Issue 3 , Pages 191-201 , 27 October 2000

Article Tools

* Image Usage & Resolution